April 5, 2018 News by Jose Marques Lopes, PhD 1st Patient Enrolls in Phase 3 Trial of ADS-5102 as Way of Improving Walking Ability, Adamas Announces A Phase 3 trial testing an oral once-a-day therapy — ADS-5102 (amantadine) extended release capsules — in multiple sclerosis (MS) patients with walking difficulties has enrolled its first participant, Adamas Pharmaceuticals announced. The multi-center, double-blind study (NCT03436199) will assess ADS-5102 in about 570 such patients at five sites…
June 17, 2016 News by Patricia Silva, PhD Adamas Reports Positive Results in Study of Drug to Treat MS Patients with Walking Difficulties Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an extended-release version of amantadine, in multiple sclerosis (MS) patients with difficulties in walking. The trial (NCT02471222), a double-blind, placebo-controlled and two-arm parallel group study, evaluated ADS-5102 given once daily at 340 mg, at bedtime, for four…
October 15, 2015 News by Patricia Silva, PhD Adamas Reports Walking Improvement in MS Models with ADS-5102 (Amantadine HCl) Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results from two non-clinical studies showing that the company’s product candidate ADS-5102 can be potentially applied as a treatment for multiple sclerosis (MS) symptoms. MS is a chronic, progressive neurodegenerative autoimmune…
October 8, 2015 News by Patricia Silva, PhD Acorda To Present New Data on MS Therapies AMPYRA and Experimental rHIgM22 at #ECTRIMS2015 Acorda Therapeutics, Inc., a company focused on therapies for neurological disorders, will present new data on its Phase 1 clinical trial evaluating rHIgM22, and five-year post-marketing safety data on AMPYRA® (dalfampridine) Extended Release Tablets (10 mg) at this year’s 31st Congress of the European Committee for Treatment and Research in…
June 12, 2015 News by Patricia Silva, PhD Adamas Begins Phase 2 Multiple Sclerosis Study for Patients with Walking Impairment Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapies for chronic disorders of the central nervous system, recently announced the beginning of a Phase 2 study that will assess the efficacy of amantadine HCl (ADS-5102) in patients with a diagnosis of multiple sclerosis (MS) who suffer from walking impairments. “We are…
September 4, 2014 News by Patricia Silva, PhD Walking Speed in MS Patients May Indicate Worsening of Disease A dynamic research team composed of doctors and scientists recently completed and published a study that sought to gain a better understanding of walking impairment, as it is manifested in patients living with multiple sclerosis (MS), a neurodegenerative disease wherein the impulse-conducting myelin sheath is attacked by the body’s own…
